VXCAD-CXR, an AI diagnostic aid solution for chest, receives approval from the Ministry of Food and Drug Safety
2024-08-20
- VXCAD-CXR, a diagnostic aid solution, detects 3 major chest diseases with artificial intelligence
- Achieved an AUROC of 0.98 or higher for diagnosing 3 types of chest diseases
- Plans to expand diagnostic scope to consolidation
and pneumonia
Vieworks, the leading provider of imaging
solution, has successfully developed and licensed a diagnostic aid solution
optimized for its X-ray detector, further strengthening its capabilities in
convergence medical imaging solutions.
Vieworks announced on the 20th that it has
acquired MFDS(Ministry of Food and Drug Safety) certification for VXCAD-CXR, an
artificial intelligence-based chest diagnostic aid solution developed by the
company's affiliated research institute.
VXCAD-CXR is an artificial intelligence-based
diagnostic aid that analyzes chest radiography images and automatically
suggests areas of suspected disease and the probability of abnormalities. It
provides information on the probability of occurrence and lesion site for three
major chest diseases, Pleural Effusion, Pneumothorax, and Nodules, enabling
medical staff to provide immediate results on-site.
The Area Under ROC curve (AUROC), a typical
metric for evaluating the performance of diagnostic assistant solutions, showed
high accuracy for detection of Pleural Effusion at 0.9993, Pneumothorax at
0.9959, and Nodules at 0.9846. In general, the closer the AUROC is to 1, the
higher the diagnostic accuracy. In the future, we plan to increase the number
of diagnosable lesions, including Consolidation and Pneumonia, through
additional data learning.
With this, Vieworks will focus on building
an integrated medical imaging solution that provides clear images with
ultra-small pixels and AI-based diagnostic aids. “We will increase our market
share by showcasing our existing hardware strengths, such as X-ray detectors,
along with diagnostic aids optimized for them,” said a Vieworks representative.
Meanwhile, Vieworks will continue to
diversify its lineup of diagnostic aid solutions, starting with the acquisition
of the domestic license for VXCAD-CXR. This year, the company will introduce
CAD (Computer-aided Diagnostics), which enables computer programs to provide
opinions on diseases, as well as two deep learning-based noise reduction
technologies that enable clearer images with lower doses, enhancing the
convenience and safety of medical staff.
“In line with the increasing demand for
emergency medical services and the sophisticated healthcare market, developing
AI-based diagnostic aids for medical device companies is becoming a necessity,
not an option. We will continue to create
high added value and innovate medical imaging solutions using our in-house
development capabilities as a driving force.”
- Previous
- List
- Next